Evidence map›Paper›PMID 33025699›Full record

ArticleJournal of clinical laboratory analysis2020

Clonal distribution of vancomycin-resistant Enterococcus faecium in Turkey and the new singleton ST733.

Fatma Erdem, Cigdem Kayacan, Oral Oncul, Alper Karagoz, Zerrin Aktas

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Global trends in antimicrobial resistance ofFrontiers in pharmacology · 2025
    Pooled it
  2. Evaluation of resistance mechanisms and susceptibility testing in Enterococcus spp.: implications of vancomycin-variable isolates and optrA-mediated resistance.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  3. Deciphering vancomycin resistance inFrontiers in microbiology · 2025
    Article
  4. Article
  5. Article
  6. Genome and transcriptome analysis ofFrontiers in microbiology · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Fatma ErdemDepartment of Clinical Microbiology, Adana City Training and Research Hospital, Adana, Turkey.ORCID https://orcid.org/0000-0002-5310-313X
Cigdem KayacanDepartment of Medical Microbiology, Faculty of Medicine, Istanbul Aydin University, Istanbul, Turkey.
Oral OnculDepartment of Infectious Disease and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Alper KaragozTurkish Public Health Agency, Ankara, Turkey.
Zerrin AktasDepartment of Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Istanbul University · TRIstanbul Aydın University · TRPublic Health Agency · GB

Funding

Istanbul University Scientific Research Projects Funding Unit 4537
6 · The paper itself

Abstract

backgroundThe aim of this study was to provide information about the spread and characteristics of the vancomycin-resistant Enterococcus faecium isolates (VREfm) in Turkey.

methodsSeventy-one nonduplicate consecutive isolates of VREfm were obtained from various clinical specimens of inpatients treated at university or training hospitals in seven regions of Turkey. Further characteristics included antibiotic susceptibility testing, pulsed-field gel electrophoresis (PFGE) of SmaI-digested genomic DNA, and multilocus sequence typing (MLST) of selected isolates. The presence of vancomycin resistance and virulence genes (esp and hyl) was investigated by polymerase chain reaction (PCR).

resultsAll VREfm isolates had MICs to vancomycin of ≥32 mg/L and contained the vanA gene. The presence of esp gene was identified in 64 and hyl in eight VREfm isolates. All VREfm showed the multiresistance phenotype, including ampicillin (99%), penicillin (99%), imipenem (99%), ciprofloxacin (87%), moxifloxacin (87%), erythromycin (97%), streptomycin (86%), gentamicin (82%), tetracycline (70%), and teicoplanin (99%). All were susceptible to tigecycline while quinupristin-dalfopristin (97%) and linezolid (93%) were the most active other agents. Analysis of the PFGE profiles showed that 53 (74.6%) VREfm isolates shared a similar electrophoretic profile, designed as type 1, and were closely related (>85%). The sequence type was identified by MLST in 44 VRE isolates with unrelated or closely related PFGE patterns. MLST revealed that nosocomial spread of VREfm resulted from dissemination of lineage C1 E faecium clones. Sequence types ST78, ST203, and ST117 were the most frequently isolated. This is the first report of ST733 around the world.

conclusionsLineage C1 clones are disseminated among clinical VREfm isolates in seven different regions in Turkey. Regarding VREfm isolates, the worldwide epidemic strains are in circulation in Turkey.

Indexed as

Cross InfectionEnterococcus faeciumGram-Positive Bacterial InfectionsVancomycin-Resistant EnterococciAdolescentAdultAgedAged, 80 and overAnti-Bacterial AgentsChildChild, PreschoolCross-Sectional StudiesDrug Resistance, BacterialElectrophoresis, Gel, Pulsed-FieldFemaleHumansAnti-Bacterial AgentsVirulence FactorsCC17MLSTPFGErisk factorsST733VRE

Identifiers

PMID33025699
PMCPMC7755804
OpenAlexW3092538379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.